Estimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorPhilip Polgreen
About this trial
A research team member will brush the inferior surface of the subjects' middle turbinate (nasal cavity) using a cytology brush to obtain the cells needed to perform our functional respiratory assays.
An individual trained in phlebotomy will draw one 3 ml lavender top tube of blood to test c-reactive protein, calprotectin, and lactoferrin. They will also draw a 5 ml gold top serum separator tube of blood to test fibroblast growth factor-19.
The participant will answer questions from the baseline survey and report their current medications interview-style with the research team member.
Eligibility criteria
Qualifiers
Previously tested and shown to be a CF carrier
English-speaking
Previously tested and shown to not be a CF carrier or CF patient
English-speaking
Disqualifiers
Currently sick with a respiratory infection
Prisoner Status
Unable to provide own written, informed consent
Trial design
Treatments tested in this trial
- Not listed
Trial groups
160 Participants
are grouped into 2 trial groupsSponsors and collaborators
Philip Polgreen
Lead sponsor
University of Iowa
Sponsor institution
National Institutes of Health (NIH)
Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborator
Source ClinicalTrials.gov